sourcing the best research evidence in ophthalmology

Dexamethasone intravitreal implant in patients with diabetic macular edema (MEAD)

Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.

Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM.

Ophthalmology. 2014 Oct;121(10):1904-14.
Full text | Metrics.

Main finding: The DEX implant provided superior VA improvement compared to sham at 3 years.

Purpose: To evaluate the safety and efficacy of dexamethasone intravitreal implant in the treatment diabetic macular edema
Study type: Randomized controlled Trial
Condition: Diabetic Macular Edema

Participants: ≥18yo, T1/2 DM, Ci-DME , VA 20/50-20/200 (6/15-6/60)

Intervention:

Groups:

Outcomes	DEX 0.7mg	DEX 0.35mg	SHAM
≥15-letter improvement in BCVA	22.2%	22.2%	12.0%
Cataract formation	67.9%	64.1%	20.4%
Trabeculectomy required	0.6%	0.3%	0

Share This Article :

Updated on March 7th, 2022